Keros Therapeutics Inc (KROS)

$10.28 +0.24 (2.39%)
Market Cap 407.24M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 1,237,500
Avg Vol 1,028,868
Day's Range N/A - N/A
Shares Out 40.56M
Stochastic %K 6%
Beta 1.39
Analysts Strong Sell
Price Target $31.00

Latest News on KROS

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Mar 31, 2025, 6:00 AM EDT - 3 days ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Feb 28, 2025, 5:00 PM EST - 4 weeks ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:01 PM EST - 5 weeks ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 30, 2025, 10:00 AM EST - 2 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 8:00 AM EST - 2 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Jan 29, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Jan 28, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Jan 27, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Jan 26, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 2 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Jan 23, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 21, 2025, 10:00 AM EST - 2 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation

Jan 20, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation

Jan 19, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out

Jan 17, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out

Jan 16, 2025, 2:30 PM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out

Keros halts hypertension treatment trial on safety issues

Jan 15, 2025, 6:41 AM EST - 2 months ago

Keros halts hypertension treatment trial on safety issues

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Jan 15, 2025, 6:30 AM EST - 2 months ago

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach Out

Dec 27, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach Out